Coronavirus | Government asks drug makers to ramp up remdesivir production to full capacity

Remdesivir is considered as a key antiviral drug in the fight against COVID-19, especially in adult patients with severe complications

April 07, 2021 09:14 pm | Updated 09:14 pm IST - New Delhi

Remdesivir antiviral injectable drug. File

Remdesivir antiviral injectable drug. File

The government on Wednesday said that all seven manufacturers of remdesivir in the country have been asked to ramp up production to full capacity by next week.

The direction comes against reports of shortages of the critical drug. Remdesivir is considered as a key antiviral drug in the fight against COVID-19, especially in adult patients with severe complications.

"There are seven players who produce remdesivir. I have asked all players to ramp up production to full capacity by next week. The drug's API is manufactured in India so there won't be a problem," Mansukh Mandaviya, Minister of State for Chemical and Fertilizers, told PTI .

Mr Mandaviya said these seven manufacturers - Mylan, Hetero, Jubiliant Life Sciences, Cipla, Dr Reddy's, Zydus Cadila and Sun Pharma - have a monthly production capacity of 31.60 lakh vials.

Letters have been despatched to all these drugmakers to ramp up production, he added.

Of the 31.60 lakh vials, Hetero produces 10.50 lakh vials a month, Cipla makes 6.20 lakh vials, 5 lakh vials are produced by Zydus Cadila and 4 lakh vials are produced by Mylan, Mr Mandaviya said.

The remaining drugmakers produce vials in the range of 1 lakh and 2.5 lakh a month, he added.

The Madhya Pradesh government has decided to procure remdesivir injections so that they could be provided free of cost for the treatment of critical COVID-19 patients from the economically weaker sections.

0 / 0
Sign in to unlock member-only benefits!
  • Access 10 free stories every month
  • Save stories to read later
  • Access to comment on every story
  • Sign-up/manage your newsletter subscriptions with a single click
  • Get notified by email for early access to discounts & offers on our products
Sign in

Comments

Comments have to be in English, and in full sentences. They cannot be abusive or personal. Please abide by our community guidelines for posting your comments.

We have migrated to a new commenting platform. If you are already a registered user of The Hindu and logged in, you may continue to engage with our articles. If you do not have an account please register and login to post comments. Users can access their older comments by logging into their accounts on Vuukle.